Nasdaq btai.

The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 …

Nasdaq btai. Things To Know About Nasdaq btai.

BTAI technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of BioXcel Therapeutics, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more.In the last trading session, 7.87 million shares of the BioXcel Therapeutics Inc (NASDAQ:BTAI) were traded, and its beta was 0.87. Most recently the company’s share price was $4.79, and it changed around $0.15 or 3.23% from the last close, which brings the market valuation of the company to $140.20M. BTAI currently trades at a discount to its ...NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...

Jun 29, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ... BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

21 Nov 2023 ... Find the latest dividend history for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.Nov 14, 2023 · BioXcel Therapeutics (NASDAQ:BTAI) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. BioXcel ...

OnkosXcel is a subsidiary of BioXcel Therapeutics, Inc. (Nasdaq: BTAI). This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91.BioXcel Therapeutics to host conference call today at 8:00 a.m. ET. NEW HAVEN, Conn., June 29, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company ...

Mar 15, 2021 · NEW HAVEN, Conn., March 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...

NEW HAVEN, Conn., April 29, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics to host conference call today at 8:00 a.m. ET. NEW HAVEN, Conn., June 29, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company ...The 5 analysts offering 12-month price forecasts for BioXcel Therapeutics Inc have a median target of 11.00, with a high estimate of 18.00 and a low estimate of 4.00. The median estimate ...Shares of BioXcel Therapeutics ( BTAI -1.80%) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501 ...Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for ...

NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...BioXcel Therapeutics (BTAI) Stock Price, News & Info | The Motley Fool Other Services BioXcel Therapeutics (NASDAQ: BTAI) $3.80 (-2.6%) -$0.10 Price as of November 30, …BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ …If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”), a commercial-stage biopharmaceutical company ...View Your Watchlist. Stock analysis for Bioxcel Therapeutics Inc (BTAI:NASDAQ CM) including stock price, stock chart, company news, key statistics, …

14 Aug 2023 ... BioXcel Therapeutics (BTAI 2.37%) stock is plummeting Monday. The clinical ... NASDAQ: BTAI. BioXcel Therapeutics. Today's Change. (2.37%) $0.09.BioXcel Therapeutics (NASDAQ:BTAI) fell ~39% pre-market Tuesday after announcing FDA feedback regarding its late-stage programs for lead product BXCL501, marketed as Igalmi sublingual film for the ...BioXcel Therapeutics Inc (NASDAQ:BTAI) showed a performance of 51.72% in past 30-days. Number of shares sold short was 5.81 million shares which calculate 1 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $10.50 to the stock, which implies a rise of 58.1% to its current value.BTAI STOCK Price - BioXcel Therapeutics Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.Nov 15, 2023 · Good news is that we have both equity as well as potential debt option in addition to, as I mentioned previously, partnering, which can be outside the U.S. for Alzheimer’s-related agitation ... BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) – Equities research analysts at HC Wainwright reduced their FY2023 EPS estimates for BioXcel Therapeutics in a research note issued to investors on Wednesday, November 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($6.63) per share for the year, down from […]

Dec 1, 2023 · When is BioXcel Therapeutics's earnings date? BioXcel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off last year's report dates. Learn more on BTAI's earnings history.

NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive ...

NEW HAVEN, Conn., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing ...BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Marpai, Inc. Class A Common Stock (MRAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Jun 2, 2023 · Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 586.04% Upside. As of ... Net Loss: BioXcel Therapeutics reported a net loss of $26.8 million for the third quarter of 2021, compared to a net loss of $24.8 million for the same period in 2020. As of September 30, 2021 ...Following a 60% decline over last year, recent gains may please BioXcel Therapeutics, Inc. (NASDAQ:BTAI) institutional owners Read full article [email protected] (Simply Wall St)BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, …View Your Watchlist. Stock analysis for Bioxcel Therapeutics Inc (BTAI:NASDAQ CM) including stock price, stock chart, company news, key statistics, …Nov 30, 2023 · The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91. The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91.

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...Find the latest on short interest for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...Instagram:https://instagram. fdsleading wealth management firmsmalaysia forexfridays stock market Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Positive Topline Results for TRANQUILITY II; Possible Trial Conduct Issues at One Clinical Site On June 29, 2023 ... stocks that are going to splitipo calender Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ...Oct 25, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ... how to calculate pips in forex Bioxcel Therapeutics (BTAI) Stock Forecast & Price TargetFintel reports that on May 30, 2023, HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 187.47% Upside. As of ...Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing.